PF 6651600

Drug Profile

PF 6651600

Alternative Names: PF-06651600; PF-6651600

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Rheumatoid arthritis; Ulcerative colitis
  • Phase I Crohn's disease

Most Recent Events

  • 30 Aug 2017 Pfizer plans a phase I trial in Healthy volunteers in Belgium (PO) (NCT03232905)
  • 01 Aug 2017 Pfizer plans a phase I trial in Healthy volunteers in Belgium (PO) (NCT03232905)
  • 03 Feb 2017 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in USA (PO) (NCT02958865)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top